

Select High-Cost Drugs



Effective January 1, 2025, select drugs provided in an inpatient hospital setting will be reimbursed separately from the APR-DRG payment. A separate claim will be submitted to receive reimbursement for select drugs during the time of inpatient services. These drugs will be reimbursed using the provider's invoice price. Invoice price must be the actual net price paid for the drug.

Providers must submit the HCPCS Code and the actual NDC# administered on an outpatient medical claim.

Cell and Gene Therapies

HCPCS Code	Drug Name
J3392	Casgevy
J3394	Lyfgenia